A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.
A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.
The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.
Influenza vaccination does not increase the risk for venous thromboembolism in patients older than 50 years of age.
Similar short-term outcomes were seen in patients with saddle and nonsaddle pulmonary embolism.
Charleston comorbidity index is an independent predictor of mortality in patients with hemodynamically stable pulmonary embolism.
Patients with either central or peripheral pulmonary embolism had positive outcomes with surgical pulmonary embolectomy for peripheral distribution of thrombus.
Obstructive sleep apnea increases patients' risk for recurrent pulmonary embolism following cessation of oral anticoagulation therapy.